Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age

References

• Gaubitz M. Epidemiology of connective tissue disorders. Rheumatology. 2006;45(Supplement 3):iii3–iii4.
   PubMedGoogle Scholar
• Spagnolo P, Cordier JF, Cottin V. Connective tissue diseases, multimorbidity and the ageing lung. Eur Respir J. 2016;47(5):1535–58.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011;38(8):1636–43.
   PubMed Web of Science ®Google Scholar
• Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti–melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta‐analysis. Arthritis Care Res. 2013;65:1316–24.
   PubMed Web of Science ®Google Scholar
• Hall JC, Casciola‐Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti–melanoma differentiation–associated protein 5–associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 2013;65:1307–15.
   PubMed Web of Science ®Google Scholar
• Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140‐kd polypeptide, CADM‐140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6.
   PubMed Web of Science ®Google Scholar
• Abe Y, Matsushita M, Tada K, Yamaji K, Takasaki Y, Tamura N. Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody–positive inflammatory myositis. Rheumatology. 2017;56(9):1492–7.
   PubMed Web of Science ®Google Scholar
• Nakashima R, Mimori T. Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia. Nihon Rinsho Men’eki Gakkai kaishi [Jpn J Clin Immunol]. 2013;36(2):71–6. Japanese.
   PubMedGoogle Scholar
• Sato S, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Tamura M, et al.; JAMI investigators. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology. 2018;57(7):1212–21.
   PubMed Web of Science ®Google Scholar
• Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597–613.
   PubMed Web of Science ®Google Scholar
• European RS, Society AT. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS executive committee, June 2001. Am J Respir Crit Care Med. 2002;165:277.
   PubMedGoogle Scholar
• Moghadam‐Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti–melanoma differentiation–associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with Amyopathic and Myopathic dermatomyositis. Arthritis Care Res. 2016;68:689–94.
   PubMed Web of Science ®Google Scholar
• Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91–9.
   PubMed Web of Science ®Google Scholar
• Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2017;27(3):536–40.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, et al. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Respir Med. 2018;140:1–5.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Yamaguchi A, Itai M, Kashiwagi C, Takehara K, Aoki S, et al. Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol. 2019;35:1–8.
   Google Scholar
• Motegi S, Fujiwara C, Sekiguchi A, Hara K, Yamaguchi K, Maeno T, et al. Clinical value of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. J Dermatol. 2019;46(3):213–8.
   PubMed Web of Science ®Google Scholar
• Motegi S, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M, et al. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol. 2019;29:511–17.
   PubMed Web of Science ®Google Scholar
• Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011;105(9):1380–7.
   PubMed Web of Science ®Google Scholar
• Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S, et al. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol. 2018;28(1):133–40.
   PubMed Web of Science ®Google Scholar
• Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. Am J Roentgenol. 1997;169(4):977–83.
   PubMed Web of Science ®Google Scholar
• Lee P, Lee TL, Ho MK, Wong W, Lau YL. Recurrent major infections in juvenile-onset systemic lupus erythematosus—a close link with long-term disease damage. Rheumatology. 2007;46(8):1290–6.
   PubMed Web of Science ®Google Scholar
• Chen IJ, Tsai WP, Wu YJ, Luo SF, Ho HH, Liou LB, et al. Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology. 2010;49(12):2429–37.
   PubMed Web of Science ®Google Scholar
• Arai T, Inoue Y, Tachibana K, Tsuyuguchi K, Nishiyama A, Sugimoto C, et al. Cytomegalovirus infection during immunosuppressive therapy for diffuse parenchymal lung disease. Respirology. 2013;18(1):117–24.
   PubMed Web of Science ®Google Scholar
• Pautas E, Cherin P, Piette J, Pelletier S, Wechsler B, Cabane J, et al. Features of polymyositis and dermatomyositis in the elderly: a case-control study. Clin Exp Rheumatol. 2000;18:241–4.
   PubMed Web of Science ®Google Scholar
• Marie I, Hatron PY, Levesque H, Hachulla E, Hellot MF, Michon-Pasturel U, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine. 1999;78(3):139–47.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, López-Soto A, Font J. Systemic autoimmune diseases in elderly patients: atypical presentation and association with neoplasia. Autoimmunity Rev. 2004;3(5):376–82.
   PubMed Web of Science ®Google Scholar
• Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther. 2011;13:R214.
   PubMed Web of Science ®Google Scholar
• Muro Y, Sugiura K, Akiyama M. Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheumatol. 2013;32(3):395–8.
   PubMed Web of Science ®Google Scholar
• Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2010;49(3):433–40.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Arita M, Morita M, Ikeo S, Ito A, Tokioka F, et al. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split? BMC Pulm Med. 2015;15(1):159.
   PubMedGoogle Scholar
• Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology. 2012;51(9):1563–70.
   PubMed Web of Science ®Google Scholar
• Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49(9):1713–9.
   PubMed Web of Science ®Google Scholar
• Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32(9):1719–26.
   PubMed Web of Science ®Google Scholar
• Morisset J, Johnson C, Rich E, Collard HR, Lee JS. Management of myositis-related interstitial lung disease. Chest. 2016;150(5):1118–28.
   PubMed Web of Science ®Google Scholar
• Sugiyama Y, Yoshimi R, Tamura M, Takeno M, Kunishita Y, Kishimoto D, et al. The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. Arthritis Res Ther. 2018;20:7.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Koike R, Sakai R, Saito K, Hirata S, Nagasawa H, et al. Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia. Mod Rheumatol. 2015;25(4):609–14.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case–control study. Br J Dermatol. 2001;144(4):825–31.
   PubMed Web of Science ®Google Scholar
• Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One. 2016;11(4):e0154285.
   PubMed Web of Science ®Google Scholar
• Yamaoka T, Doi C, Yokomi A, Tanemura A, Murota H, Tani M, et al. Anti-MDA5 antibody-positive dermatomyositis with lethal progressive interstitial lung disease and advanced gastric cancer. Eur J Dermatol. 2014;24:490–1.
   PubMed Web of Science ®Google Scholar
• Ichiyasu H, Sakamoto Y, Yoshida C, Sakamoto K, Fujita R, Nakayama G, et al. Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy. Respir Med Case Rep. 2017;20:51–4.
   PubMed Web of Science ®Google Scholar
• Moghadam-Kia S, Oddis C, Aggarwal R. Interstitial lung disease in myositis. Crmr. 2015;11(2):130–7.
   Google Scholar